Privium Fund Management B.V. Arcutis Biotherapeutics, Inc. Transaction History
Privium Fund Management B.V.
- $436 Million
- Q4 2024
A detailed history of Privium Fund Management B.V. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 325,709 shares of ARQT stock, worth $4.3 Million. This represents 1.04% of its overall portfolio holdings.
Number of Shares
325,709Holding current value
$4.3 Million% of portfolio
1.04%Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
207Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC12.3MShares$163 Million0.11% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$145 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$142 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$116 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$114 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $795M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...